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Background: Epoxyeicosatrienoic acids (EETs) are derived from arachidonic acid by cytochrome P450 (CYP) and
metabolized by soluble epoxide hydrolase (sEH). EETs have been associated with cardiovascular disease, diabetes
and several cancer diseases. However, the distribution in tissue and role of CYP2C8, 2C9, 2J2 and sEH in human
breast carcinogenesis remains uncertain.
Methods: Breast cancer (BC) and adjacent noncancerous tissue was obtained from 40 breast cancer patients in
the Chaoshan region in China from 2010 to 2012. The level of 14,15-EET/14,15-DHET in BC patients was detected
by ELISA; the expression and distribution of CYP2C8, 2C9, 2J2 and sEH was determined by quantitative RT-PCR
and immunohistochemical staining; and cell proliferation and migration was analyzed by MTT and transwell assays,
respectively.
Results: The median 14,15-EET and 14,15-EET/DHET level was 2.5-fold higher in BC than noncancerous tissue. The mRNA
and protein levels of CYP2C8, 2C9 and 2J2 were higher, and sEH was lower in BC than noncancerous tissue. Furthermore,
CYP2C8 and 2C9 protein levels positively correlated with Ki67 status, and CYP2J2 levels positively correlated with
histological grade and tumor size. The sEH protein level negatively correlated with tumor size, estrogen receptors
and Ki67. In MDA-MB-231 cells, siRNA knockdown of CYP2C8, 2C9 or 2J2 reduced cell proliferation, by 24.5%, 29.13%, or
22.7% and decreased cell migration by 49.1%, 44.9%, and 50.9%, respectively. Similarly, with adenovirus overexpression
of sEH, both cell proliferation and migration rates were reduced by 31.4% and 45.8%, respectively.
Conclusions: The present study shows that elevated EET levels in BC tissues are associated with upregulation of CYP2C8,
2C9, and 2J2, and downregulation of sEH, and are also associated with aggressive cell behavior in BC patients.
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Breast cancer (BC) is the most frequently diagnosed cancer
and the leading cause of cancer deaths in women in both
developed and developing countries worldwide. In 2008,
1.38 million new cases of BC were diagnosed and 458,400
people died due to BC [1]. The etiology of BC appears to
be related to a long menstrual history, nulliparity, re-
cent use of postmenopausal hormone therapy or oral con-
traceptives, late age at first birth and alcohol consumption
[2]. However, substantial numbers of patients still experi-
ence metastatic disease, and further improvements in sur-
vival depend on a better understanding and identification
of cellular targets within the malignant cell for novel
therapeutic development and for targeting of optimal
therapies. Thus, the exact causes of BC and its malignant
potential are still unclear.
Epoxyeicosatrienoic acids (EETs), derived from arachi-
donic acid by cytochrome P450 (CYP), promote the patho-
genesis of various human cancers [3-7]. Four regioisomeric
EETs (5,6-EET, 8,9-EET, 11,12-EET, and 14,15-EET) are
active lipid signaling molecules and are anti-inflammatory,
proliferative, and angiogenic, and easily spread within
several tissues under both physiologic and pathologic
conditions. In humans, CYP2C8, 2C9 and 2J2 subfamily
members participate in the synthesis of EETs, which are
then quickly metabolized by soluble epoxide hydrolase
(sEH) into their respective diols in most tissues [8,9]. Thus,
the balance of CYP2C8, 2C9, and 2J2, as well as sEH
expression is responsible for sustaining EET concentration.
CYP2C8, 2C9, 2J2 and sEH expression has been detected
in several tumor tissues and cells, which supports a role
for EETs in cancer. Both CYP2C8 and 2C9 are highly
expressed in human malignant neoplasms, such as renal
carcinoma, lung adenocarcinoma (but not lung squamous
cell carcinoma), ductal breast carcinoma, colon adenocar-
cinoma, basal cell carcinoma, bladder transitional cell car-
cinoma, ovarian adenocarcinoma, endometrial carcinoma,
and prostate adenocarcinoma. In contrast, CYP2C8 ex-
pression has been found to be downregulated five-fold
in esophageal adenocarcinoma as compared with para-
cancerous tissue [10]. CYP2J2 expression is elevated in
human malignant tumors, such as esophageal, liver, breast,
lung, and colorectal cancers, and high levels of EETs are
detected in urine and blood of patients with these cancers
[3,11]. In contrast, pancreatic or prostate adenocarcinoma
or BC tissue do not show CYP2J2 expression, and the
enzyme is detected in less than 50% of lung squamous cell
carcinoma and less than 15% of lung adenocarcinoma
samples [10,12,13]. This decrease in arachidonic acid
epoxidation in certain tumors may allow arachidonic
acid to be metabolized to other eicosanoids [12]. Loss
of sEH has been reported in renal tumors, hepatocellular
carcinoma and hepatoma cells [10,14,15], which would
result in an enhanced role of EETs in carcinogenesis.However, upregulation of sEH expression has been found
in other types of cancers, such as seminoma, cholangiocar-
cinoma, and advanced ovarian cancer, as compared with
normal tissue or early-stage cancer [3,10,11].
Although many studies have focused on EET synthesis
and metabolic enzymes in several cancers, the characteris-
tics and roles of EET isoforms such as CYP2C8, 2C9, and
2J2, and sEH in BC remains poorly understood. A recent
microarray assay of BC tissue showed CYP2C expression
in 80% of the tissues, with weak or moderate immunoreac-
tivity [13], whereas other studies found high prevalence
and modest or strong immunoreactivity [3,11]. We con-
ducted a retrospective investigation of the level of EET
and expression and distribution of CYP2C8, 2C9, and 2J2
and sEH in human BC tissue and adjacent noncancerous
tissue. We further investigated the role of EETs and sEH
during breast cancer proliferation and migration.
Methods
Patients
The study protocol was performed according to the
Declaration of Helsinki and was approved by the Ethics
Committee of the Cancer Hospital of Shantou University
Medical College. All patients were from the Shantou region
of China and gave their signed informed consent for the
use of biological samples.
All patients underwent modified radical mastectomy or
mastectomy, and no patients received lumpectomy. Fresh
noncancerous tissues were collected at least 5 cm away
from the margins of tumors for paired malignant lesions
from 40 patients (mean age 44.5 ± 8.7 years) in the Cancer
Hospital of Shantou University Medical College from
2010 to 2012. Non-cancerous tissue, confirmed by a path-
ologist, was defined as normal breast tissue not presented
with ductal carcinoma in situ (DCIS), atypical hyperplasia
or benign breast disease. Changes in tumor size, node me-
tastasis and histological grade were determined according
to the World Health Organization histological classifica-
tion criteria [16].
14,15-EET/DHET detection
Episomal and esterified 14,15-DHET (including episomal
and transformed DHET from 14,15-EET by sEH) in BC
tissues was determined by use of an ELISA kit (Detroit
R&D, USA). Briefly, we homogenized 30 mg tissue in
0.4 mL of H2O, containing 0.001 mg TPP (triphenylpho-
sphine, an antioxidant), for all tumor and non-tumor
tissues before ethyl acetate extraction. Total protein con-
centration was measured with a BSA kit according to the
protocol (Takara Biotechnology [DALIAN] Co.) and used
to normalize EET and DHET measurements. Ethyl acetate
extracts were incubated in ethanol and acetic acid for 18 h
at room temperature to allow complete EET hydrolysis to
DHET. Then, 130 uL of Sample Dilution Buffer was added
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justed to pH 7.4, if necessary, then DHET, which included
DHET converted from EET, was measured using a 14,15-
DHET ELISA kit. At the same time, the DHET level was
measured without hydrolysis of EET in the same sample,
then subtracted from the EET +DHET level to obtain the
EET level in the sample. Inability to detect levels of EETs
indicated that EET was totally hydrolyzed to DHET. The
efficiency of conversion of EET to DHET according to the
free of EET formation activity measurement after the EET
hydrolyzed to DHET by ethanol and acetic acid.
Immunohistochemical (IHC) staining
After excision, clinical samples were fixed immediately
in 4% paraformaldehyde for 24 hr, embedded in paraffin
and sectioned at 4 μm thickness for IHC staining with
primary antibody for CYP2C8 (1:100, Proteintech Group,
Chicago, IL, USA), 2C9 (1:100, Biosynthesis, Beijing), and
2J2 (1:100, Abgent, San Diego, CA), as well as for sEH
(1:100, Santa Cruz Biotechnology, Santa Cruz, CA) as
described [13,17]. IgG or phosphate-buffered saline (PBS)
was a negative or blank control, respectively. Then, the
slides were incubated with polyclonal peroxidase-conjugated
anti-mouse/rabbit IgG (PV9000; Zymed Laboratories, South
San Francisco, CA). Sections were stained with 100 μl
AEC chromogen (Maxim.bio Co.) and restained with
haematoxylin for visualization of nuclei.
The scoring of positive immunoreactivity was as de-
scribed previously [4,18] with modifications: 0, <25%; 1,
25–50%; 2, 50–75%; 3, >75%. The intensity of staining
was scored as 0, absence of signal; 2, low-intensity signal
(light red); 2, moderate-intensity signal (red); and 3, high-
intensity signal (dark red). The final score for each case
was the total of the frequency and intensity scores, with
the following classification: 0 or 1, negative (−); 2 or 3,
moderately positive (+); and 4 to 6, highly positive (++).
Cell culture, transfection and infection
Human BC MDA-MB-231 cells were maintained in
DMEM (Invitrogen, Carlsbad, CA) supplemented with
10% heat-inactivated fetal bovine serum at 37°C in a
humidified atmosphere containing 5% CO2. After culture
for 24 hr at 50% to 60% density, cells were transfected with
40 μmol/L siRNA pools for CYP2C8, 2C9 or 2J2 by the Jet
PEI method (Polyplus, San Marcos, CA) or infected with
adenovirus sEH (Ad-sEH) [19], a recombinant Ad express-
ing human-EPXH2. Ad-GFP was an infection control.
Quantitative reverse transcription-PCR (qRT-PCR)
Total RNA was isolated from tissue and cells with use of
TRIzol reagent (Invitrogen), and 0.5 μg RNA was converted
to cDNA with the SuperScript II Reverse Transcriptase
kit (Invitrogen). Primers for CYP2C8, 2C9, 2J2, sEH and
β-actin were as we described previously [17]. qRT-PCRamplification involved the PrimeScript Real-Time RT-PCR
reagent kit (Takara Biotechnology [DALIAN] Co.) and
Applied Biosystems Prism 7300 (Invitrogen). DNase-
treated RNA was amplified without reverse transcriptase
as a negative control. Human hepatocellular carcinoma
tissue RNA was a positive control and water was a blank
control. Amplification of β-actin was an internal control.
The relative expressions of CYPs and sEH were normal-
ized to their corresponding normal control tissue.
MTT assay
MDA-MB-231 cells were inoculated at 5000 cells per well
of a 96-well plate, allowed to attach for 24 hr, and then
treated with siRNA or Ad-sEH/Ad-GFP at the indicated
amounts for another 24 hr. Cell proliferation was analyzed
by use of the MTT Cell Proliferation and Cytotoxicity
Assay Kit (Beyotime, China). The corrected absorbance of
each sample was calculated by comparison with that of
the siRNA control or Ad-GFP as an infection control.
Cell transwell assay for migration
MDA-MB-231 cells treated with siRNA or Ad-sEH/Ad-
GFP were inoculated at 2 × 105 in transwell inserts with
0.8 μm pore size (Corning, New York, USA) in 24-well
plates for 24 h. Cells in the bottom inside of the mem-
branes were removed. Migrating cells on the outside mem-
brane were washed and stained with crystal violet for
10 min. The number of migrating cells was measured
by counting 5 randomly chosen fields under a micro-
scope [20].
Statistical analysis
Statistical analysis involved use of SPSS 16.0 (SPSS Inc.,
Chicago, IL). The normality of variables was assessed. The
Mann–Whitney two-sample test was used to assess differ-
ences in 14,15-EET levels and mRNA expression of
CYP2C8, 2C9, and 2J2, as well as sEH in BC and adjacent
noncancerous tissue. Spearman correlation was used to
analyze the correlation of clinicopathological variables and
CYP2C8, 2C9, and 2J2, as well as sEH protein expression.
Student’s t test was used for statistical analysis of cell pro-
liferation and migration assays. Data are expressed as
median (interquartile range [IQR]) or mean ± SD. Each
experiment was performed at least in triplicate. P <0.05
was considered statistically significant.
Results
14,15-EET levels in BC and noncancerous human tissue
EETs and their synthetic and metabolic enzymes (CYP2C8,
2C9, 2J2 and sEH) promote angiogenesis, inflammation,
and carcinogenesis [5,6,17]. We detected the 14,15-EET
level in cancer tissue from 40 BC patients. The median
14,15-EET level was 2.5-fold higher in BC tissue than






































































Figure 1 Intracellular levels of 14,15-EET (A), 14,15-EET/DHET
(B) and total 14,15-DHET (C) in breast cancer and paired adjacent
noncancerous regions. Boxes and whiskers represent the 25th–75th and
10th–90th percentiles, respectively; the median is the central line in each
box. The P value was calculated by the Mann–Whitney two-sample test.
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(Figure 1A) and the median ratio of 14,15-EET to epi-
somal 14,15-DHET was higher in BC tissue than non-
cancerous tissue (0.80 [0.64-0.85] vs. 0.58 [0.37-0.75];
p <0.001) (Figure 1B), with no difference in total 14,15-
DHET level (including episomal and transformed DHET
from 14,15-EET by sEH) (Figure 1C).
Expression of enzymes for EET synthesis and degradation,
and their association with clinicopathological variables in
BC patients
The mRNA levels of enzymes responsible for EET syn-
thesis ranged from 4.4- to 7.5-fold greater BC than non-
cancerous tissue: CYP2C8 (4.40-fold), 2C9 (7.55-fold) and
2J2 (7.19-fold) (Figure 2). In contrast, sEH, responsible for
EET degradation, was reduced (52.8% of normal) (Figure 2).
Also, CYP2C9 protein expression was the most prevalent
in the 40 cases of BC and adjacent noncancerous tissue, ac-
counting for about 60% (24/40) and 45% (18/40), respect-
ively, of the enzymes responsible for EET synthesis. Equal
protein expression was observed for CYP2C8 and 2J2 in
BC (30%) and noncancerous (10%) tissue (Table 1). The
proportion of sEH protein expression was 40% (16/40) and
60% (24/40) in BC and adjacent noncancerous tissue, re-
spectively. In addition, immunoreactivity was increased for
CYP2C8 and 2J2 but not 2C9 and decreased for sEH in BC
tissue (Table 1). These results indicate that, consistent with
the elevated EET levels reported above, the enzymes re-
sponsible for EET synthesis are elevated, whereas the
enzyme responsible for EET degradation is decreased in
BC tissue.
The CYP2C8 protein level correlated with estrogen re-
ceptors (ER) and Ki67 status (P =0.011 and P =0.037, re-
spectively); the CYP2C9 level correlated with Ki67 status
(P =0.007); the CYP2J2 level correlated with histological
grade and tumor size (P =0.036 and P =0.047, respectively);
and sEH level was negatively correlated with tumor size,
ER and Ki67 status (P =0.021; P =0.003 and P <0.001, re-
spectively) (Table 2). No relationship was found with age,
lymph-node metastasis, histological grade, C-erbB-2 and
progesterone receptor (PR) expression.
Effect of CYP450 and sEH on proliferation and migration
of BC cells
To further investigate the functional role of CYP2C8, 2C9,
and 2J2 and sEH in BC cells, we transfected CYP2C8,







































































































Figure 2 Expression and distribution of CYP2C8, 2C9, and 2J2, and sEH in breast cancer. qRT-PCR analysis of mRNA expression (A-D) and
immunohistochemistry (E) of CYP2C8, 2C9, and 2J2, and sEH in breast cancer and paired adjacent noncancerous tissue. Human hepatocellular
carcinoma tissues were used as a positive control. The red staining was by AEC and the nuclei were lightly stained with haematoxylin (original
magnification 200X).
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57.9 ± 10.6%, 48.0 ± 4.5% and 63.5 ± 3.6%, and cell prolifera-
tion decreased by 24.5 ± 7.2%, 29.1 ± 5.0%, and 22.7 ± 3.5%,
respectively (Figure 3C). Meanwhile, the proportion of mi-
grating cells was also decreased by about 49.1 ± 10.2%,
44.9 ± 7.9%, and 50.9 ± 11.1%, respectively (Figure 3D, E).
To overexpress sEH exogenously, we infected MDA-MB-
231 cells with Ad-sEH. At 24 hr after infection, sEH
mRNA was approximately 125.3-fold higher with Ad-sEH
than Ad-GFP infection (Figure 3B). With Ad-sEH infection,cell proliferation was decreased about 31.4 ± 5.3% as
compared with Ad-GFP transfection (Figure 3C) and
the proportion of migrating cells was decreased about
45.8 ± 9.1%, (Figure 3E).
Discussion
The level of EETs, as well as their synthetic and metabolic
enzymes, has attracted great interest as potential thera-
peutic targets for renal disease, cardiovascular disease,
inflammation and cancer [3,6,9,21]. Indeed, previous





Breast cancer tissue, no. of samples (%) P value*
- + ++
CYP2C8 - 28 (70%) 4 (10%) 4 (10%) 0.019
+ 0 0 2 (5%)
++ 0 0 2 (5%)
CYP2C9 - 12 (30%) 6 (15%) 4 (10%) 0.094
+ 4 (10%) 2 (5%) 6 (15%)
++ 0 2 (5%) 4 (10%)
CYP2J2 - 28 (70%) 6 (15%) 2 (5%) 0.019
+ 0 0 2 (5%)
++ 0 0 2 (5%)
sEH - 10 (25%) 6 (15%) 0 0.034
+ 6 (15%) 2 (5%) 4 (10%)
++ 8 (20%) 2 (5%) 2 (5%)
Sum of frequency and intensity scores: 0 or 1, negative (−); 2 or 3, moderately positive (+); 4 to 6, highly positive (++).
*Spearman correlation was used to analyze the correlation of clinicopathological variables and EET-related genes expression.
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http://www.biomedcentral.com/1471-2407/14/841in vivo and in vitro studies, including ours, have shown
that CYP2C8, 2C9, and 2JC promote cancer cell prolifera-
tion, migration, angiogenesis, survival and invasion in
several types of cancer such as hepatocellular carcinoma,
esophageal carcinoma, and malignant hematologic disease
[5,6,17]. However, the characteristics of EET expression
and their synthetic and metabolic enzymes are not clear inTable 2 Relationship of EET-related gene expression and clini
Variable CYP2C8
- + P value* -
Age, years ≤50 12 4 0.573 8
>50 16 8 8
Histological grade I 8 2 0.821 8
II 12 6 6
III 8 4 2
Tumor size, cm ≤2 8 0 0.058 6
2-5 18 10 10
≥5 2 2 0
Lymph node metastasis Negative 14 4 0.332 12
Positive 14 8 4
ER status - 6 8 0.011 4
+ 22 4 12
Ki67 proportion ≤14% 8 8 0.037 2
>14% 20 4 14
C-erb-B2 staining −/+ 22 6 0.13 14
++/+++ 6 6 2
PR status - 6 2 1 2
+ 22 10 14
ER, estrogen receptors; PR, progesterone receptor.
*Spearman correlation was used to analyze the correlation of clinicopathological vaBC. In the present study, we find a high level of 14,15-
EET with increasing CYP2C8, 2C9 and 2J2 expression,
and decreasing sEH mRNA and protein expression in BC
as compared with adjacent noncancerous tissue. We
further show that knockdown of CYP2C8, 2C9 and 2J2
or overexpression of sEH inhibits the proliferation and
migration of BC cells.cal characteristics of BC patients
CYP2C9 CYP2J2 sEH
+ P value* - + P value* - + P value*
8 0.292 12 4 0.573 12 10 0.618
16 16 8 12 6
6 0.879 14 2 0.036 6 4 0.131
8 10 4 8 10
10 4 6 10 2
3 0.089 9 1 0.047 2 7 0.021
17 17 7 20 7
4 2 4 2 2
12 0.114 19 5 0.166 10 6 0.792
12 9 7 14 10
10 0.279 8 6 0.193 4 10 0.003
14 20 6 20 6
14 0.007 10 6 0.49 4 12 <0.001
10 18 6 20 4
14 0.079 24 8 0.221 20 10 0.159
10 4 4 4 6
6 0.439 8 0 0.079 8 5 0.89
18 20 12 16 11
riables and EET-related genes expression.
Figure 3 Blockage of cancer-derived EETs by siRNA targeting CYP or overexpression of sEH inhibits proliferation and migration of
breast cancer cells. RT-PCR analysis of mRNA expression of CYP2C8, 2C9, and 2J2, and sEH in MDA-MB-231 cells treated with siRNA (A) or
adenovirus-sEH (B) for 24 hr. (C) MTT assay of cell proliferation, expressed as the normalized mean OD490. (D) Transwell assay for cell migration.
The number of migrated cells was measured by counting 5 randomly chosen fields under a microscope. (E) Representative transwell assay of cells
stained with crystal violet (200X). Data are mean ± SD from 3 independent experiments each performed in triplicate (*P < 0.05; **P < 0.01 compared
with Si-RNA control. ##P < 0.01 compared with Ad-GFP).
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http://www.biomedcentral.com/1471-2407/14/841CYP450s were thought to promote cancer progression
primarily in the major metabolic organs, such as liver,
kidney and epithelium. However, recent studies have
detected a sustained high level of EETs by upregulated
CYP2C8, 2C9 and 2J2, or downregulated sEH in various
cancers such as renal, lung, basal cell, bladder, ovarian,
colon, and prostate cell carcinomas [3,7,10,22]. BC tissueshows a relatively high percentage and strong immunopo-
sitivity of CYP4X1, 2S1 and 2U among twenty-one P450
panels [13]. CYP3A4 is also a highly active arachidonic
acid epoxygenase that promotes Stat3-mediated BC cell
growth in part via (±)-14,15-EET biosynthesis [18]. Simi-
larly, CYP2C is detected in 80% of BC tissue, based on
a recent tissue microarray study [13].
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http://www.biomedcentral.com/1471-2407/14/841We find that CYP2C9 and 2C8 are expressed in 60%
and 30% of BC tissue, respectively. Both CYP2C8 and 2C9
protein levels positively correlate with Ki67 status, a bio-
marker for cell proliferation. The modest immunoreactive
staining we find for CYP2J2 protein is consistent with
previous studies [3,10]. Despite the relatively low CYP2J2
prevalence, CYP2J2 protein expression is positively corre-
lated with histological grade and tumor size, which is con-
sistent with previous in vivo and in vitro studies [3,10,21].
Moreover, sEH expression is lower in BC than adjacent
noncancerous tissue and negatively correlates with tumor
size, ER and Ki67 expression. The elevated CYP2C8, 2C9,
and 2J2 expression observed here may represent aggres-
siveness of BC cells and might predict worse cell behavior
in BC patients.
Evidence from Panigrahy and colleagues has shown that
elevated EET levels in endothelial cells leads to the devel-
opment of tumor-associated angiogenesis and promotes
metastasis [6,23]. In vitro and in vivo studies also indicate
that EETs may promote cancer progression by directly
inducing cancer cell proliferation, survival, migration,
and invasion, by changing the tumor microenvironment
(inducing angiogenesis) and/or inducing immunosup-
pression in an autocrine and/or paracrine manner. This
mechanism supports the role of CYP450s as potential
tumor-promoting enzymes [3,5]. For example, downregu-
lated CYP2C expression and/or its enzymatic activity may
provide a safe and effective strategy to treat non-small cell
lung cancer [22]. Treatment of glioblastoma-bearing rats
with CYP epoxygenase inhibitors attenuated tumor growth
and tumor-associated angiogenesis [24]. Similarly, overex-
pression of sEH decreased HepG2 cell proliferation and
induced cell cycle arrest [19]. Treating mice with a CYP2J
peptide inhibited tumor growth by activating host antitu-
mor immunity at an initial stage of an implanted murine
bladder tumor [25]. In our study, consistent with the el-
evated 14,15-EET levels in BC tissue, elevated CYP2C8,
2C9 and 2J2 expression and reduced sEH expression
might contribute to increased 14,15-EET levels and pro-
mote breast carcinogenesis. This result is further supported
by our in vitro findings showing that knockdown of
CYP2C8, 2C9 or 2J2 and overexpression of sEH inhibits
the proliferation and slows the migration of BC cells.
Although the expression and role of CYP2C8, 2C9,
and 2J2, and sEH have been reported in several tumors,
their regulation is largely unknown. Evidence from our
previous study showed that hypermethylation of the sEH
promoter in HepG2 cells suppresses its transcription by
an SP-1–dependent mechanism [19]. Human CYP2J2 and
2C8 are post-transcriptionally regulated by microRNAs
let-7b and 103/107, respectively [26,27]. EET receptor(s)
have not yet been clearly identified, but the putative
GPCR/PPAR/RXR pathway, endothelial growth factor
receptor (EGFR) and vascular endothelial growth factorsignaling are potential targets for EETs to promote tumor
growth and metastasis [28-30]. Multiple pathways, includ-
ing EGFR/PI3K/Akt, EGFR/mitogen-activated protein kin-
ase, tumor necrosis factor-α and pro-metastatic matrix
metalloproteinases are also involved in the mechanism by
which EETs induce cancer cell proliferation and survival
[3,7,21]. Thus, to further understand the molecular and
biological mechanisms, and develop EET receptor antago-
nists as antitumor agents of EETs in malignant diseases,
the EET receptor must be identified.
Conclusion
In conclusion, increased EET levels in BC might be due
to upregulation of CYP2C8, 2C9, and 2J2 and downregu-
lation of sEH, and knockdown of CYP2C8, 2C9, and 2J2
and overexpression of sEH could partially attenuate the
proliferation and migration of BC cells. These molecules
might be novel therapeutic targets for the treatment of BC.
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